Abstract
After binding to the neurokinin-1 (NK-1) receptor, substance P (SP) induces tumor cell proliferation, angiogenesis, and the migration of tumor cells for invasion and metastasis. After binding to NK-1 receptors, NK-1 receptor antagonists inhibit tumor cell proliferation, angiogenesis and the migration of tumor cells. These antagonists are broad-spectrum antitumor drugs. In addition, in the host they display beneficial effects: anxiolytic, antiemetic, neuroprotector, nephroprotector, hepatoprotector, antiinflammatory and analgesic. In combination therapy with classic cytostatics, NK-1 receptor antagonists have synergic effects and minimize the side-effects of these classic drugs. Thus, NK-1 receptor antagonists could offer a new and promising generation of anticancer drugs.
Keywords: Substance P, neoangiogenesis, metastasis, tumor cells, apoptosis, preprotachykinin A, in situ, malignant melanomas, gastric motility, SP-immunoreactivity, NK-1 receptors
Mini-Reviews in Medicinal Chemistry
Title:NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs
Volume: 12 Issue: 7
Author(s): M. Munoz and R. Covenas
Affiliation:
Keywords: Substance P, neoangiogenesis, metastasis, tumor cells, apoptosis, preprotachykinin A, in situ, malignant melanomas, gastric motility, SP-immunoreactivity, NK-1 receptors
Abstract: After binding to the neurokinin-1 (NK-1) receptor, substance P (SP) induces tumor cell proliferation, angiogenesis, and the migration of tumor cells for invasion and metastasis. After binding to NK-1 receptors, NK-1 receptor antagonists inhibit tumor cell proliferation, angiogenesis and the migration of tumor cells. These antagonists are broad-spectrum antitumor drugs. In addition, in the host they display beneficial effects: anxiolytic, antiemetic, neuroprotector, nephroprotector, hepatoprotector, antiinflammatory and analgesic. In combination therapy with classic cytostatics, NK-1 receptor antagonists have synergic effects and minimize the side-effects of these classic drugs. Thus, NK-1 receptor antagonists could offer a new and promising generation of anticancer drugs.
Export Options
About this article
Cite this article as:
Munoz M. and Covenas R., NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs, Mini-Reviews in Medicinal Chemistry 2012; 12 (7) . https://dx.doi.org/10.2174/138955712800626692
DOI https://dx.doi.org/10.2174/138955712800626692 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interactions Between Cholinergic and Fibroblast Growth Factor Receptors in Brain Trophism and Plasticity
Current Protein & Peptide Science Artemia species: An Important Tool to Screen General Toxicity Samples
Current Pharmaceutical Design Targeting Protein-Protein and Protein-Nucleic Acid Interactions for Anti-HIV Therapy
Current Pharmaceutical Design Sigma Receptors and Cocaine Abuse
Current Topics in Medicinal Chemistry MicroRNAs as Cancer Biomarkers
MicroRNA A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Modified Polysaccharides as Carriers for Biomolecules
Pharmaceutical Nanotechnology Application of In Vivo Electroporation to Cancer Gene Therapy
Current Gene Therapy Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells
Current Drug Delivery CD44 and EpCAM: Cancer-Initiating Cell Markers
Current Molecular Medicine Editorial (Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology)
Current Pharmacogenomics and Personalized Medicine The Multifarious Medical Applications of Carbon Curvatures: A Cohort review
Current Bioactive Compounds Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment
Current Signal Transduction Therapy Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design Lessons Learned from the Irinotecan Metabolic Pathway
Current Medicinal Chemistry Influence of the Bystander Effect on HSV-tk / GCV Gene Therapy. A Review.
Current Gene Therapy Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics
Current Medicinal Chemistry Cellular Uptake and Organ Accumulation of Amphipolar Metallocorroles with Cytoprotective and Cytotoxic Properties
Anti-Cancer Agents in Medicinal Chemistry